Abstract Rationale Approximately 20-40% of patients with Chronic Obstructive Pulmonary Disease (COPD) exhibit Type 2 (T2) inflammation, characterized by elevated blood eosinophil count (BEC). However, the prevalence of T2 comorbidities in COPD patients and its relationship with BEC remains underexplored. The aim of this analysis is to describe the prevalence of T2 comorbidities in COPD among T2-high and T2-low eosinophil subgroups. Methods A descriptive, retrospective, analysis was conducted using real-world data from Optum’s de-identified Market Clarity Data (Optum® Market Clarity). COPD and T2 comorbidities were identified using ICD-10 codes. Patients diagnosed with both asthma and COPD were excluded. T2-high and T2-low subgroups were defined by BEC 300/µL and 100/µL, respectively, over the past 12 months. Results Between October 2015 and March 2024, 6,749,956 patients were identified with COPD. The most frequent T2 comorbidities were allergic rhinitis (32%), chronic rhinosinusitis with nasal polyps (CRSwNP) (17%), and atopic dermatitis (5%). Among the 3,354,422 COPD patients with available eosinophil levels, T2 comorbidities were prevalent even in the T2-low subgroup (EOS 100/µL) (Fig). Compared to T2-high COPD patients, T2-low COPD patients had similar prevalence rates of allergic rhinitis (33% vs. 41%), CRSwNP (18% vs. 22%), and atopic dermatitis (5% vs. 7%). Conclusions T2 comorbidities are highly prevalent in COPD patients, even among those with low eosinophil levels. This suggests that COPD may be more closely associated with T2 inflammation than previously recognized. Consequently, it may be useful to include the presence of T2 comorbidities as a defining feature of T2 COPD in those with low BEC. Figure. Prevalence of T2 comorbidities among COPD patients Abbreviation: AD, atopic dermatitis; CRSwNP, chronic rhinosinusitis with nasal polyps; CSU, chronic spontaneous urticaria; EoE, eosinophilic esophagitis This abstract is funded by: Sanofi
Soumagne et al. (Fri,) studied this question.